Phase II trial of Intercell's Japanese encephalitis vaccine, IC 51, compared with a mouse-brain Japanese encephalitis vaccine, for the prevention of encephalitis virus infections in paediatric patients in India.

Trial Profile

Phase II trial of Intercell's Japanese encephalitis vaccine, IC 51, compared with a mouse-brain Japanese encephalitis vaccine, for the prevention of encephalitis virus infections in paediatric patients in India.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2010

At a glance

  • Drugs Aluminium hydroxide; IC 51; Japanese encephalitis vaccine
  • Indications Encephalitis virus infections; Japanese encephalitis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Biological E Limited; Intercell
  • Most Recent Events

    • 08 Jan 2010 Results reported in Vaccine.
    • 10 Dec 2008 Results data presented at the American Society for Tropical Medicine and Hygiene Annual Meeting (ASTMH) 2008, as reported in a media release from Intercell.
    • 15 Apr 2008 Preliminary results available, according to an Intercell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top